Insulin analogues: impact of cell model characteristics on results and conclusions regarding mitogenic properties

References

• 1 Bahr M, Kolter T, Seipke G, Eckel J. Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells.  Eur J Pharmacol. 320 259-265 1997; 
• 2 Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Häring H U. The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin.  Horm Metab Res. 30 123-129 1998; 
• 3 Drejer K. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake.  Diabetes Metab Rev. 8 259-285 1992; 
• 4 Hansen B F, Danielsen G M, Drejer K, Sorensen A R, Wiberg F C, Klein H H, Lundemose A G. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency.  Biochem J. 315 271-279 1996; 
• 5 Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.  Diabetes. 49 999-1005 2000; 
• 6 Lamothe B, Baudry A, Christoffersen C T, De-Meyts P, Jami J, Bucchini D, Joshi R L. Insulin receptor-deficient cells as a new tool for dissecting complex interplay in insulin and insulin-like growth factors.  FEBS Lett. 426 381-385 1998; 
• 7 Slieker L J, Brooke G S, DiMarchi R D, Flora D B, Green L K, Hoffmann J A, Long H B, Fan L, Shields J E, Sundell K L, Surface P L, Chance R E. Diabetologia. 40 (Suppl 2) S54-S61 1997;